Recurrent fallopian tube carcinoma: TP53 mutation and clinical course

Int J Gynecol Pathol. 2000 Apr;19(2):145-51. doi: 10.1097/00004347-200004000-00008.

Abstract

Primary fallopian tube carcinoma is a rare, aggressive gynecological cancer; little is known about its cause. Previous studies have indicated that p53 immunopositivity is correlated with short-term survival in primary fallopian tube carcinoma. We examined p53 and p21/WAF1 immunostaining and TP53 mutation in exons 5 to 8 by single-stranded conformation polymorphism and constant denaturant gel electrophoresis in nine cases of primary fallopian tube carcinoma and their metastases/recurrences from patients who survived for between a few months and more than 20 years after diagnosis. We found that 1.) p53 immunopositivity without detectable p21/WAF1 immunostaining did not correlate with TP53 mutations in the conserved domains; 2.) mutations in TP53 occurred in two metastases/recurrences but not in their corresponding primary tumors; 3.) in two cancers, a TP53 mutation was observed in the primary tumor but not in the metastases/recurrences; 4.) constant denaturant gel electrophoresis seems to be more sensitive than single-stranded conformation polymorphism in detecting TP53 mutations; and 5.) in the nine cases studied, p53 immunoreactivity and/or TP53 mutation analysis did not correlate with tumor progression, survival, or response to treatment.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use
  • Cyclin-Dependent Kinase Inhibitor p21
  • Cyclins / analysis
  • DNA Mutational Analysis
  • Exons
  • Fallopian Tube Neoplasms / genetics*
  • Fallopian Tube Neoplasms / surgery
  • Fallopian Tube Neoplasms / therapy
  • Female
  • Genes, p53 / genetics*
  • Humans
  • Immunohistochemistry
  • Middle Aged
  • Mutation*
  • Neoplasm Recurrence, Local / genetics*
  • Polymorphism, Single-Stranded Conformational
  • Radiotherapy
  • Treatment Outcome
  • Tumor Suppressor Protein p53 / analysis

Substances

  • Antineoplastic Agents
  • CDKN1A protein, human
  • Cyclin-Dependent Kinase Inhibitor p21
  • Cyclins
  • Tumor Suppressor Protein p53